Iterion Therapeutics
Aundrietta Duncan possesses extensive experience in non-clinical development and research within the pharmaceutical and therapeutic sectors. Currently serving as Sr. Director of Research and Non-clinical Development at Iterion Therapeutics, Aundrietta previously held positions as Director and Associate Director of Non-clinical Development at Salarius Pharmaceuticals. Additional experience includes serving as Associate Principal and Entrepreneurship Fellow at Fannin Innovation Studio. Aundrietta's roles reflect a strong background in leadership and innovation in drug development.
This person is not in any teams
Iterion Therapeutics
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivintdemonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.It was founded in 2010 and is headquartered in Houston, Texas.